Zymeworks (ZYME) Total Non-Current Liabilities (2021 - 2026)
Zymeworks recorded quarterly Total Non-Current Liabilities of $314.3 million in Q1 2026, up 304.32% quarter-over-quarter from $77.7 million in Q4 2025, and up 215.3% year-over-year from $99.7 million in Q1 2025.
Zymeworks' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $314.3 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 215.3% year-over-year to $314.3 million; the TTM figure through Mar 2026 stood at $314.3 million (up 215.3% YoY), while the FY2025 annual figure was $77.7 million, down 37.0% from the prior year.
- Total Non-Current Liabilities came in at $314.3 million for Q1 2026 at Zymeworks, up from $77.7 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $314.3 million in Q1 2026 to a low of $73.1 million in Q2 2025.
- A 5-year average of $126.8 million and a median of $117.6 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities slumped 37.0% in 2025 and soared 215.3% in 2026, its largest moves.
- Zymeworks' Total Non-Current Liabilities stood at $154.1 million in 2022, then slipped by 25.79% to $114.4 million in 2023, then gained by 7.89% to $123.4 million in 2024, then plunged by 37.0% to $77.7 million in 2025, then soared by 304.32% to $314.3 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $314.3 million, $77.7 million, and $76.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | 314.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 314.35 Mn |
| Dec 31, 2025 | 77.75 Mn |
| Sep 30, 2025 | 76.93 Mn |
| Jun 30, 2025 | 73.05 Mn |
| Mar 31, 2025 | 99.70 Mn |
| Dec 31, 2024 | 123.40 Mn |
| Sep 30, 2024 | 119.25 Mn |
| Jun 30, 2024 | 108.24 Mn |
| Mar 31, 2024 | 114.16 Mn |
| Dec 31, 2023 | 114.37 Mn |
| Sep 30, 2023 | 131.73 Mn |
| Jun 30, 2023 | 152.08 Mn |
| Mar 31, 2023 | 125.70 Mn |
| Dec 31, 2022 | 154.13 Mn |
| Sep 30, 2022 | 117.57 Mn |
| Dec 31, 2021 | 137.29 Mn |